Mobile

Double blind, double dummy, multinational, multicenter, parallel-group design clinical trial of superiority of CHF 1535 1 puff in a b.i.d regimen administered via an HFA-propellant-pMDI versus a doubl...

Mise à jour : Il y a 4 ans
Référence : EUCTR2004-000718-37

Double blind, double dummy, multinational, multicenter, parallel-group design clinical trial of superiority of CHF 1535 1 puff in a b.i.d regimen administered via an HFA-propellant-pMDI versus a double equivalent dose of Beclomethasone Dipropionate in b.i.d regimen administered via an CFC-propellant–pMDI in a 12 week treatment period of mild to moderate persistent asthma in adults patients

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To demonstrate the clinical superiority in terms of pulmonary function of CHF 1535 (formoterol and beclomethasone fixed combination) vs. a double dose of beclomethasone alone in the 12-week treatment period of mild to moderate persistent asthma in adult patients

Critère d'inclusion

  • Mild to moderate adult asthmatic patients

Liens